Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Slides:

Advertisements

Similar presentations

Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.

Advertisements

MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification by Paolo Strati, and.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

by James O. Armitage, and Dan L. Longo

by Susan L. Slager, Kari G. Rabe, Sara J. Achenbach, Celine M

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Tax fingerprint in adult T-cell leukemia

One giant leap for pediatric AMKL

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

by Wendy Cozen, Dalin Li, Timothy Best, David J

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

Protease inhibitors potentiate chemotherapy-induced neutropenia

by Jessica A. Reese, Xiaoning Li, Manfred Hauben, Richard H

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset.

Tait D. Shanafelt, MD, Timothy G. Call, MD Mayo Clinic Proceedings

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Overall survival by SCT versus observation in first complete remission

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

by Wendy Lim, Sara K. Vesely, and James N. George

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

Patient Tregs express normal levels of suppression.

by Jan J. Cornelissen, and Didier Blaise

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia by Susan M. O'Brien, Nicole Lamanna, Thomas.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.

Cold agglutinin disease

Presentation transcript:

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia by Tait D. Shanafelt, Matthew T. Drake, Matthew J. Maurer, Cristine Allmer, Kari G. Rabe, Susan L. Slager, George J. Weiner, Timothy G. Call, Brian K. Link, Clive S. Zent, Neil E. Kay, Curtis A. Hanson, Thomas E. Witzig, and James R. Cerhan Blood Volume 117(5):1492-1498 February 3, 2011 ©2011 by American Society of Hematology

Month of sample collection and 25(OH)D levels (ng/mL) in the discovery cohort (n = 390). Tait D. Shanafelt et al. Blood 2011;117:1492-1498 ©2011 by American Society of Hematology

TTT and OS based on vitamin D insufficiency. TTT and OS based on vitamin D insufficiency. (A) TTT in the discovery cohort (n = 390). (B) OS in the discovery cohort (n = 390). (C) TTT in the confirmation cohort (n = 152). (D) OS in the confirmation cohort (n = 153). Tait D. Shanafelt et al. Blood 2011;117:1492-1498 ©2011 by American Society of Hematology

Overall survival based on vitamin D insufficiency in both cohorts. Overall survival based on vitamin D insufficiency in both cohorts. (A) OS among Rai 0 patients (n = 259). (B) OS of IGHV-unmutated patients based on vitamin D insufficiency (n = 230). (C) OS of ZAP-70–positive patients based on vitamin D insufficiency (n = 185). (D) OS of patients with standard-risk FISH (eg, normal, trisomy 12, 13q−) based on vitamin D insufficiency (n = 393). Tait D. Shanafelt et al. Blood 2011;117:1492-1498 ©2011 by American Society of Hematology